Role of natural killer cells innate protection against lethal Ebola virus infection

Journal of Experimental Medicine

Volumn 200, Issue 2, 2004, Pages 169-179

  Warfield, Kelly L ^a   Perkins, Jeremy G ^b   Swenson, Dana L ^a   Deal, Emily M ^a   Bosio, Catharine M ^a   Aman, M Javad ^a   Yokoyama, Wayne M ^c   Young, Howard A ^a   Bavari, Sina ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Filoviruses; Glycoprotein; Immunity; Matrix protein; Virus like particles

Indexed keywords

GLYCOPROTEIN; MATRIX PROTEIN; PROTEIN P40; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; EBOLA VIRUS; EMBRYO; EVIDENCE BASED MEDICINE; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; LETHALITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; SURVIVAL; VIRUS HEMORRHAGIC FEVER; WILD TYPE;

ANIMALS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, ATOMIC FORCE; PORE FORMING CYTOTOXIC PROTEINS; SPLEEN; TIME FACTORS;

EID: 3242782481     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20032141     Document Type: Article

References (53)

1. Feldmann, H., W. Slenczka, and H.D. Klenk. 1996. Emerging and reemerging of filoviruses. Arch. Virol. Suppl. 11:77-100.
2. Feldmann, H., S. Jones, H.D. Klenk, and H.J. Schnittler. 2003. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3:677-685.
3. Johnson, E., N. Jaax, J. White, and P. Jahrling. 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:227-236.
4. Stroher, U., E. West, H. Bugany, H.D. Klenk, H.J. Schnitder, and H. Feldmann. 2001. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75:11025-11033.
5. Mahanty, S., K. Hutchinson, S. Agarwal, M. McRae, P.E. Rollin, and B. Pulendran. 2003. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170:2797-2801.
6. Bosio, C.M., M.J. Aman, C. Grogan, R. Hogan, G. Ruthel, D. Negley, M. Mohamadzadeh, S. Bavari, and A. Schmaljohn. 2003. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188:1630-1638.
7. Baize, S., E.M. Leroy, M.C. Georges-Courbot, M. Capron, J. Lansoud-Soukate, P. Debre, S.P. Fisher-Hoch, J.B. McCormick, and A.J. Georges. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5:423-426.
8. Leroy, E.M., S. Baize, V.E. Volchkov, S.P. Fisher-Hoch, M.C. Georges-Courbot, J. Lansoud-Soukate, M. Capron, P. Debre, J.B. McCormick, and A.J. Georges. 2000. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 355:2210-2215.
9. Leroy, E.M., S. Baize, P. Debre, J. Lansoud-Soukate, and E. Mavoungou. 2001. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Immunol. 124:453-460.
10. Baize, S., E.M. Leroy, A.J. Georges, M.C. Georges-Courbot, M. Capron, I. Bedjabaga, J. Lansoud-Soukate, and E. Mavoungou. 2002. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128:163-168.
11. Biron, C.A., K.B. Nguyen, G.C. Pien, L.P. Cousens, and T.P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:189-220.
12. Guidotti, L.G., and F.V. Chisari. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65-91.
13. Lieberman, L.A., and C.A. Hunter. 2002. Regulatory pathways involved in the infection-induced production of IFN-gamma by NK cells. Microbes Infect. 4:1531-1538.
14. Scalzo, A.A. 2002. Successful control of viruses by NK cells - a balance of opposing forces? Trends Microbiol. 10:470-474.
15. Rager-Zisman, B., P.C. Quan, M. Rosner, J.R. Moller, and B.R. Bloom. 1987. Role of NK cells in protection of mice against herpes simplex virus-1 infection. J. Immunol. 138: 884-888.
16. Bukowski, J.F., J.F. Warner, G. Dennert, and R.M. Welsh. 1985. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J. Exp. Med. 161:40-52.
17. Biron, C.A., K.S. Byron, and J.L. Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320:1731-1735.
18. Warfield, K.L., C.M. Bosio, B.C. Welcher, E.M. Deal, M. Mohamadzadeh, A. Schmaljohn, M.J. Aman, and S. Bavari. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. USA. 100:15889-15894.
19. Jahrling, P.B., J. Geisbert, J.R. Swearengen, G.P. Jaax, T. Lewis, J.W. Huggins, J.J. Schmidt, J.W. LeDuc, and C.J. Peters. 1996. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl. 11:135-140.
20. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1999. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179:S248-S258.
21. Hevey, M., D. Negley, J. Geisbert, P. Jahrling, and A. Schmaljohn. 1997. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 239:206-216.
22. Kim, S., K. Iizuka, H.L. Aguila, I.L. Weissman, and W.M. Yokoyama. 2000. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA. 97:2731-2736.
23. Bavari, S., C.M. Bosio, E. Wiegand, G. Ruthel, A.B. Will, T.W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn, and M.J. Aman. 2002. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195:593-602.
24. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6:1258-1266.
25. He, Y., A.A. Pimenov, J.V. Nayak, J. Plowey, L.D. Falo, Jr., and L. Huang. 2000. Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum. Gene Ther. 11:547-554.
26. Jacobs, D.M., and D.C. Morrison. 1977. Inhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. J. Immunol. 118:21-27.
27. Wilson, J.A., M. Hevey, R. Bakken, S. Guest, M. Bray, A.L. Schmaljohn, and M.K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 287: 1664-1666.
28. Wilson, J.A., M. Bray, R. Bakken, and M.K. Hart. 2001. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 286:384-390.
29. Yokoyama, W.M., and A.A. Scalzo. 2002. Natural killer cell activation receptors in innate immunity to infection. Microbes Infect. 4:1513-1521.
30. Swenson, D.L., K.L. Warfield, K. Kuehl, T. Larsen, M.C. Hevey, A. Schmaljohn, S. Bavari, and M.J. Aman. 2004. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol. Med. Microbiol. 40:27-31.
31. Rice, G.P., R.D. Schrier, and M.B. Oldstone. 1984. Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc. Natl. Acad. Sci. USA. 81:6134-6138.
32. Chehimi, J., S. Bandyopadhyay, K. Prakash, B. Perussia, N.F. Hassan, H. Kawashima, D. Campbell, J. Kornbluth, and S.E. Starr. 1991. In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates. J. Virol. 65:1812-1822.
33. Kanegane, H., K. Nomura, T. Miyawaki, and G. Tosato. 2002. Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit. Rev. Oncol. Hematol. 44:239-249.
34. Valentin, A., and G.N. Pavlakis. 2003. Natural killer cells are persistently infected and resistant to direct killing by HIV-1. Anticancer Res. 23:2071-2075.
35. Timmins, J., S. Scianimanico, G. Schoehn, and W. Weissenhorn. 2001. Vesicular release of ebola virus matrix protein VP40. Virology. 283:1-6.
36. Noda, T., H. Sagara, E. Suzuki, A. Takada, H. Kida, and Y. Kawaoka. 2002. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 76: 4855-4865.
37. Feldmann, H., V.E. Volchkov, V.A. Volchkova, and H.D. Klenk. 1999. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch. Virol. Suppl. 15:159-169.
38. Basler, C. F., X. Wang, E. Muhlberger, V. Volchkov, J. Paragas, H.D. Klenk, A. Garcia-Sastre, and P. Palese. 2000. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. USA. 97:12289-12294.
39. Basler, C.F., A. Mikulasova, L. Martinez-Sobrido, J. Paragas, E. Muhlberger, M. Bray, H.D. Klenk, P. Palese, and A. Garcia-Sastre. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77:7945-7956.
40. Ignatiev, G.M., A.A. Dadaeva, S.V. Luchko, and A.A. Chepurnov. 2000. Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs. Immunol. Lett. 71:131-140.
41. Geisbert, T.W., L.E. Hensley, T. Larsen, H.A. Young, D.S. Reed, J.B. Geisbert, D.P. Scott, E. Kagan, P.B. Jahrling, and K.J. Davis. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163:2347-2370.
42. Arase, H., E.S. Mocarski, A.E. Campbell, A.B. Hill, and L.L. Lanier. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science. 296:1323-1326.
43. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T.I. Arnon, Y. Bushkin, D.M. Davis, J.L. Strominger, J.W. Yewdell, and A. Porgador. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 409:1055-1060.
44. Arnon, T.I., M. Lev, G. Katz, Y. Chernobrov, A. Porgador, and O. Mandelboim. 2001. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. 31: 2680-2689.
45. Razumov, I.A., E.F. Belanov, A.A. Bukreev, and E.I. Kazachinkskaia. 1998. Monoclonal antibodies to Marburg virus proteins and their immunochemical characteristics. [In Russian.] Vopr. Virusol. 43:274-279.
46. Gomis-Ruth, F.X., A. Dessen, J. Timmins, A. Bracher, L. Kolesnikowa, S. Becker, H.D. Klenk, and W. Weissenhorn. 2003. The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure (Camb). 11:423-433.
47. Panchal, R.G., G. Ruthel, T.A. Kenny, G.H. Kallstrom, D. Lane, S.S. Badie, L. Li, S. Bavari, and M.J. Aman. 2003. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl. Acad. Sci. USA. 100:15936-15941.
48. Jasenosky, L.D., G. Neumann, I. Lukashevich, and Y. Kawaoka. 2001. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J. Virol. 75:5205-5214.
49. van den Broek, M.F., and H. Hengartner. 2000. The role of perforin in infections and tumour surveillance. Exp. Physiol. 85:681-685.
50. Ghiasi, H., S. Cai, G. Perng, A.B. Nesburn, and S.L. Wechsler. 1999. Perforin pathway is essential for protection of mice against lethal ocular HSV-1 challenge but not corneal scarring. Virus Res. 65:97-101.
51. Tay, C.H., and R.M. Welsh. 1997. Distinct organ-dependent mechanisms for the control of murine cytomegalovims infection by natural killer cells. J. Virol. 71:267-275.
52. Tay, C.H., L.Y. Yu, V. Kumar, L. Mason, J.R. Ortaldo, and R.M. Welsh. 1999. The role of LY49 NK cell subsets in the regulation of murine cytomegalovirus infections. J. Immunol. 162:718-726.
53. Brown, M.G., A.O. Dokun, J.W. Heusel, H.R. Smith, D.L. Beckman, E.A. Blattenberger, C.E. Dubbelde, L.R. Stone, A.A. Scalzo, and W.M. Yokoyama. 2001. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science. 292:934-937.